Combat the 21st century global public health problems through revolutionary i-αVLP Technology.

SEE OUR TECHNOLOGY
406, 2015

VLP Therapeutics to Initiate Collaboration with National Cancer Center in Japan

VLP Therapeutics, LLC. (“VLP”) announced that it has initiated a research collaboration with the National Cancer Center’s National Cancer Center Research Institute in Japan. The collaboration will help facilitate VLP’s research and development of cancer vaccine candidates.
406, 2015

VLP Therapeutics to Initiate Collaboration with Johns Hopkins University Bloomberg School of Public Health

VLP Therapeutics, LLC. (“VLP”) announced that it has initiated a research collaboration with John’s Hopkins University Bloomberg School of Public Health to research VLP’s malaria vaccine candidates.
104, 2015

VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University

VLP Therapeutics, LLC. (“VLP”) announced that it has entered into a research collaboration with the Institute of Tropical Medicine at Nagasaki University in Japan. The collaboration will facilitate VLP’s research and development of dengue vaccine candidates.

Vaccines are one of the most important inventions in the past centuries. The successful vaccines save millions of lives to prevent infectious diseases and do so in a cost effective way. We are exploring the vaccine technology to expand other new important fields with high unmet medical needs such as cancer, lifestyle chronic diseases, neurological diseases as well as infectious diseases through cutting edge i-αVLP vaccine technology. We believe that this i-αVLP vaccine technology has a potential to be a breakthrough technology, and our company would like to make significant contributions to the global public health.